Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lynk Pharma Reports Third-Gen JAK Inhibitor Meets Safety Goals in Phase I Trial

publication date: Apr 4, 2023

Lynk Pharmaceuticals of Hangzhou said a China Phase I trial of its third-gen, intestinal-restricted JAK inhibitor showed the candidate has good safety, tolerability and pharmacokinetics. LNK01003 is an oral small molecule JAK inhibitor aimed at ulcerative colitis and related diseases. Its mechanism concentrates exposure of the drug in the gastrointestinal tract, which is expected to avoid systemic immunosuppression and reduce side effects. At the same time, Lynk says its candidate delivers increased amounts of the drug to gastrointestinal tissues, increasing the inhibitory effect on multiple inflammatory cytokines that cause IBD. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here